TRH: mediator of prolactin in the prostate?
Thanks to our preoccupation with androgen ablative therapy, no significant progress has been made in combating prostate cancer (PCa) in 50 years. Also, there have been only limited advances in medical treatment of benign prostatic hyperplasia (BPH). The intent of this essay is to explore the mode of participation of prolactin (Prl) in prostatic physiology in the hope that such knowledge will reveal new avenues through which both BPH and PCa can be opposed-even prevented. An especially novel aspect of this study is the recognition of the presence and androgen- and prolactin-dependent concentration of the tripeptide, thyrotropin-releasing hormone (TRH) in prostatic tissue. It is hypothesized that, whereas TRH is the hypothalamic stimulus of hypophyseal Prl secretion, it may, in the prostate, serve as the mediator of Prl's independent and androgen-dependent controls of the gland's growth and function. Through an overview of these relationships, methods are suggested both for their study and for their adaptation to early detection and prevention of imminent pathogenesis.
Farnsworth
W E
WE
Department of Urology, Northwestern University Medical School, Chicago, IL 60611-3009.
D000818:Animals; D006801:Humans; D008297:Male; D008954:Models, Biological; D011388:Prolactin / Q000502:physiology*; D011467:Prostate / Q000502:physiology*; D011470:Prostatic Hyperplasia / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000517:prevention & control; D013973:Thyrotropin-Releasing Hormone / Q000502:physiology*
D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin